FindTrial
Sign In

Role of zinc supplementation in pediatric nephrotic syndrome

Role of zinc supplementation in reducing relapse rate in pediatric nephrotic syndrome: a randomized- controlled trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/095938
Enrollment
92
Registered
2025-10-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N040- Nephrotic syndrome with minor glomerular abnormality

Interventions

Intervention1: RDA doses of Zinc: Zinc RDA as per WHO guidelines in addition to standard care Control Intervention1: Standard care: Standard care

Sponsors

AIIMS Rishikesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed or any follow up case of steroid-sensitive nephrotic syndrome Informed consent from parents or legal guardians

Exclusion criteria

Exclusion criteria: 1.Steroid-resistant nephrotic syndrome 2.Congenital or secondary nephrotic syndrome 3.Severe or chronic infections (e.g., tuberculosis, HIV, hepatitis) 4.Chronic systemic illnesses or known zinc metabolism disorders 5.Ongoing zinc supplementation

Design outcomes

Primary

MeasureTime frame
frequency of relapse ratesTimepoint: six months from study enrolment—

Secondary

MeasureTime frame
To assess the effect of zinc supplementation on infection-related relapse rates. To assess the effect of zinc on the time to first relapse after remission. To evaluate the number of infection episodes during the study period.Timepoint: 6 months duration—

Countries

India

Contacts

Public ContactDr Prashant Kumar Verma

AIIMS RIshikesh

2004pkv@gmail.com9412592332

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026